Global Cephalosporin Drugs Market 2015-2019

セファロスポリン系薬の世界市場2015-2019

◆タイトル:Global Cephalosporin Drugs Market 2015-2019
◆商品コード:IRTNTR7550
◆調査・発行会社:Technavio (Infiniti Research Ltd.)
◆発行日:2015年9月23日
◆ページ数:100
◆資料形式:pdf / 英語
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:製薬
◆販売価格オプション(消費税別)
Single UserUSD3,000 ⇒換算¥339,000見積依頼/購入/質問フォーム
Five UserUSD3,500 ⇒換算¥395,500見積依頼/購入/質問フォーム
Enterprise License(全社内共有可)USD4,500 ⇒換算¥508,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、資料に記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はTechnavio (Infiniti Research Ltd.)の日本における正規販売代理店です。

【資料の概要】

当調査レポートでは、セファロスポリン系薬の世界市場について調査・分析し、エグゼクティブサマリー、市場概観、市場概観、業界の構造分析、セファロスポリン系薬の世界市場規模及び予測、製品別分析、投与経路(ROA)別分析、市場シェア、地域別分析、市場の成長要因、市場の課題、市場動向、競争状況、主要企業(ベンダー)分析などの情報をお届けいたします。

・エグゼクティブサマリー
・市場概観
・業界の構造分析
・セファロスポリン系薬の世界市場:市場規模及び予測
・セファロスポリン系薬の世界市場:製品別分析
・セファロスポリン系薬の世界市場:投与経路(ROA)別分析
・セファロスポリン系薬の世界市場:地域別分析
・市場シェア
・市場の成長要因
・市場の課題
・市場動向
・競争状況
・主要企業(ベンダー)分析
...

※上記の和訳は最新内容ではない場合があります。下記の英文概要・目次が最新版です。

About cephalosporins
Cephalosporins are bactericidal antibiotics and act by inhibiting cell wall synthesis. They inhibit a wide variety of gram-positive and gram-negative bacteria. They are considered broad-spectrum antibiotics with similar activities to those of ampicillin. They are sometimes grouped into “generations” by their antimicrobial properties. Cephalosporin drugs can be grouped into five classes or generations. The gram-negative antimicrobial property significantly increases with each newer generation of cephalosporin.

Technavio’s analysts forecast the global cephalosporin drugs market to grow at a CAGR of 3.21% over the period 2014-2019.

[Covered in this report]
In this report, Technavio covers the present scenario and growth prospects of the global cephalosporin drugs market for 2015-2019. To calculate the market size, the report considers revenue generated from the sales of various prescription drugs along with the generic drugs used for the treatment of various infectious diseases caused by the different strains of bacteria.

Technavio’s report, Global Cephalosporin Drugs Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, APAC, and EMEA; it also covers the landscape of the global cephalosporin drugs market and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.

[Key regions]
• Americas
• APAC
• EMEA

[Key vendors]
• Allergan
• Astellas
• Bristol-Myers Squibb
• GlaxoSmithKline
• Merck
• Pfizer
• Sandoz
• Teva Pharmaceuticals

[Other prominent vendors]
• Abbott
• Aspen Pharmacare
• AstraZeneca
• Aurobindo Pharma
• Basilea Pharmaceuticals
• Baxter
• Biocon
• Corden Pharma
• Cornerstone Therapeutics
• Eli Lilly
• F. Hoffmann-La Roche
• Flynn Pharma
• Hospira
• Incepta Pharmaceuticals
• Johnson & Johnson
• Kyorin Pharmaceutical
• Lupin Pharmaceuticals
• Orchid Pharma
• Par Pharmaceutical
• Pernix Therapeutics
• Sanofi
• Shionogi
• Sun Pharmaceutical
• Takeda Pharma
• Theravance Biopharma
• Wockhardt

[Market driver]
• Special regulatory designation for pipeline molecules
• For a full, detailed list, view our report

[Market challenge]
• Development of drug resistance
• For a full, detailed list, view our report

[Market trend]
• Use of combination therapies
• For a full, detailed list, view our report

[Key questions answered in this report]
• What will the market size be in 2019 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

【資料の目次】

PART 01: Executive summary
Highlights

PART 02: Scope of the report
Market overview
Top vendor offerings

PART 03: Market research methodology
Research methodology
Economic indicators

PART 04: Introduction
Key market highlights

PART 05: Cephalosporin overview
Introduction
Precursors of cephalosporins
Mechanism of action
General principles for use of antibiotics
Clinical uses
Epidemiology

PART 06: Overview on the consumption of antibiotics
Latin America
Europe
APAC

PART 07: Legislation relating to antibiotic use in the US

PART 08: Market landscape
Market overview
Market size and forecast
Five forces analysis

PART 09: Market segmentation by generation of cephalosporin
First-generation cephalosporins
Second-generation cephalosporins
Third-generation cephalosporins
Fourth-generation cephalosporins
Fifth-generation cephalosporins

PART 10: Market segmentation by route of administration
Injection
Oral

PART 11: Geographical segmentation
Segmentation of global cephalosporin drugs market by geography
Cephalosporin drugs market in Americas
Cephalosporin drugs market in EMEA
Cephalosporin drugs market in APAC

PART 12: Market drivers
Special regulatory designation for pipeline molecules
Rise in prevalence of infectious diseases
Increase in awareness

PART 13: Impact of drivers

PART 14: Market challenges
Development of drug resistance
High generic penetration
Weak pipeline

PART 15: Impact of drivers and challenges

PART 16: Market trends
Use of combination therapies
Increase in M&A
Increasing irrational use of cephalosporins

PART 17: Vendor landscape
Competitive scenario
Market share analysis 2014
Other prominent vendors

PART 18: Key vendor analysis
Allergan
Astellas
Bristol-Myers Squibb
GSK
Merck
Pfizer
Sandoz
Teva Pharmaceuticals

PART 19: Appendix
List of abbreviations

PART 20: Explore Technavio

[List of Exhibits]

Exhibit 01: Product offerings
Exhibit 02: Evolution of cephalosporin drugs
Exhibit 03: Overview of the activity of different generations of cephalosporin drugs
Exhibit 04: General principles involved in use of antibiotics
Exhibit 05: Estimated number of cases for nosocomial infections in the US 2011
Exhibit 06: Number of cases of E.coli in the UK 2012-2014
Exhibit 07: Legislation relating to the use of antibiotics in the US
Exhibit 08: Global cephalosporin drugs market 2014-2019 ($ millions)
Exhibit 09: Five forces analysis
Exhibit 10: Global cephalosporin drugs market segment by generation
Exhibit 11: Overview of activity of different generations of cephalosporins
Exhibit 12: Evolution of different generations of cephalosporin drugs
Exhibit 13: Global cephalosporin drugs market segment by route of administration
Exhibit 14: Different generations of cephalosporin drugs by route of administration
Exhibit 15: Global cephalosporin drugs market segment by geography 2014
Exhibit 16: Global cephalosporin drugs market revenue by geography 2014-2019 ($ millions)
Exhibit 17: Cephalosporin drugs market in Americas 2014-2019 ($ millions)
Exhibit 18: Percentage share of cephalosporin market in Americas
Exhibit 19: Percentage share of market by generation of cephalosporin in the US based on revenue 2014
Exhibit 20: Cephalosporin drugs market in EMEA 2014-2019 ($ millions)
Exhibit 21: Percentage share of cephalosporin drugs market in EMEA
Exhibit 22: Percentage share of market by generation of cephalosporin in EU based on revenue 2014
Exhibit 23: Cephalosporin drugs market in APAC 2014-2019 ($ millions)
Exhibit 24: Impact of drivers
Exhibit 25: Cephalosporin resistant strains according to the period of development of resistance
Exhibit 26: Impact of drivers and challenges
Exhibit 27: Allergan: YoY growth and revenue generated from net product sales of anti-infective drugs 2011-2013 ($ millions)
Exhibit 28: Allergan: Key takeaways
Exhibit 29: Astellas: Key takeaways
Exhibit 30: Bristol-Myers Squibb: Key takeaways
Exhibit 31: GSK: Key takeaways
Exhibit 32: Merck: Key takeaways
Exhibit 33: Pfizer: Key takeaways
Exhibit 34: Sandoz: Key takeaways
Exhibit 35: Teva Pharmaceuticals: Key takeaways
Exhibit 36: Allergan: Business segmentation by product revenue 2014
Exhibit 37: Allergan: Business segmentation by revenue 2013 and 2014 ($ billions)
Exhibit 38: Allergan: Geographical segmentation by revenue 2014
Exhibit 39: Astellas: Product segmentation by revenue 2015
Exhibit 40: Astellas: Product segmentation by revenue 2014 and 2015 ($ billions)
Exhibit 41: Astellas: Geographical segmentation by revenue 2015
Exhibit 42: Bristol-Myers Squibb: Segmentation by revenue 2014
Exhibit 43: Bristol-Myers Squibb: Segmentation by revenue 2013 and 2014 ($ billions)
Exhibit 44: Bristol-Myers Squibb: Geographical segmentation by revenue 2014
Exhibit 45: GSK: Business segmentation by revenue 2014
Exhibit 46: GSK: Business segmentation by revenue 2013 and 2014 ($ billions)
Exhibit 47: GSK: Geographical segmentation by revenue 2014
Exhibit 48: Merck: Business segmentation by revenue 2014
Exhibit 49: Merck: Business segmentation by revenue 2013 and 2014 ($ billions)
Exhibit 50: Merck: Geographical segmentation by revenue 2014
Exhibit 51: Pfizer: Business segmentation by revenue 2014
Exhibit 52: Pfizer business segmentation by revenue 2013 and 2014 ($ billions)
Exhibit 53: Pfizer: Geographical segmentation by revenue 2014
Exhibit 54: Sandoz: Business segmentation by revenue 2014
Exhibit 55: Teva Pharmaceuticals: Business segmentation by revenue 2014
Exhibit 56: Teva Pharmaceuticals: Business segmentation by revenue 2013 and 2014
Exhibit 57: Teva Pharmaceuticals: Geographical segmentation by revenue 2014



【掲載企業】

Allergan, Astellas, Bristol-Myers Squibb, GSK, Merck, Pfizer, Sandoz, Teva, Abbott, Aspen Pharmacare, AstraZeneca, Aurobindo Pharma, Basilea Pharmaceuticals, Baxter, Biocon, Corden Pharma, Eli Lilly, F. Hoffmann-La Roche, Flynn Pharma, Hospira, Incepta Pharmaceuticals, Johnson & Johnson, Kyorin Pharmaceutical, Lupin Pharmaceuticals, Orchid Pharma, Par Pharmaceutical, Pernix Therapeutics, Sanofi, Shionogi, Sun Pharmaceutical, Takeda Pharma, Theravance Biopharma, Wockhardt.

【資料のキーワード】

セファロスポリン系薬、セフェム系抗生物質、治療、医薬品、第一世代セファロスポリン、第二世代セファロスポリン、第三世代セファロスポリン、第四世代セファロスポリン、第五世代セファロスポリン

【調査方法】

一次資料による調査(業界専門家、ベンダー、代理店、顧客等を対象にしたデプスインタビュー調査など)及び二次資料による調査(Technavio独自のプラットフォーム、産業書籍、企業報告書、ニュース記事、アナリストレポート、貿易協会、政府機関発行データなど)

【免責事項】
※当資料上の情報/データは調査会社が信頼できると判断した情報源から入手したものに基づき作成しましたが、その正確性・完全性を保証するものではありません。当資料に記載された情報/データ/見解/仮説などは作成時点又は発行時点における調査会社の判断であり、その後の状況変化に応じて変更される場合があります。当資料上の情報/データに基づいたお客様の意思決定又は実行による結果について、調査会社/発行会社/販売会社H&Iグローバルリサーチはその責を負いかねますのでご了承ください。英文資料の紹介ページにおける日本語題名/概要/目次はH&Iグローバルリサーチが翻訳した内容であり、翻訳の正確性・完全性を保証するものではありません。

[セファロスポリン系薬の世界市場2015-2019]についてメールでお問い合わせはこちら


◆H&Iグローバルリサーチ株式会社のお客様(例)◆